214 related articles for article (PubMed ID: 19923313)
1. Elevated International Normalized Ratio associated with concurrent use of sorafenib and warfarin.
Moretti LV; Montalvo RO
Am J Health Syst Pharm; 2009 Dec; 66(23):2123-5. PubMed ID: 19923313
[TBL] [Abstract][Full Text] [Related]
2. [Gastrointestinal hemorrhage associated with concurrent use of sorafenib and warfarin for hepatocellular carcinoma].
Shiozawa K; Watanabe M; Hirano N; Wakui N; Kikuchi Y; Hara F; Ishii K; Iida K; Sumino Y
Gan To Kagaku Ryoho; 2011 Oct; 38(10):1713-5. PubMed ID: 21996974
[TBL] [Abstract][Full Text] [Related]
3. Elevated International Normalized Ratio in a patient concurrently using warfarin and vismodegib.
Lim S; Houranieh J; Crawford R
Am J Health Syst Pharm; 2014 Feb; 71(3):200-3. PubMed ID: 24429012
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib in advanced hepatocellular carcinoma.
Spinzi G; Paggi S
N Engl J Med; 2008 Dec; 359(23):2497-8; author reply 2498-9. PubMed ID: 19052134
[No Abstract] [Full Text] [Related]
5. Elevated International Normalized Ratio values in a patient receiving warfarin and ceftaroline.
Farhat NM; Hutchinson LS; Peters M
Am J Health Syst Pharm; 2016 Jan; 73(2):56-9. PubMed ID: 26721534
[TBL] [Abstract][Full Text] [Related]
6. [Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma].
Reig M; Matilla A; Bustamante J; Castells L; de La Mata M; Delgado M; Moreno JM; Forner A; Varela M
Gastroenterol Hepatol; 2010 Dec; 33(10):741-52. PubMed ID: 20851505
[No Abstract] [Full Text] [Related]
7. Elevated International Normalized Ratio in a Patient Taking Warfarin and Mauby: A Case Report.
Sorbera M; Joseph T; DiGregorio RV
J Pharm Pract; 2017 Oct; 30(5):567-570. PubMed ID: 27543375
[TBL] [Abstract][Full Text] [Related]
8. [Hepatocellular carcinoma - long-term treatable disease].
Fínek J
Klin Onkol; 2012; 25(4):287-9. PubMed ID: 22920170
[TBL] [Abstract][Full Text] [Related]
9. Elevated international normalized ratio associated with concomitant warfarin and erlotinib.
Thomas KS; Billingsley A; Amarshi N; Nair BA
Am J Health Syst Pharm; 2010 Sep; 67(17):1426-9. PubMed ID: 20720241
[TBL] [Abstract][Full Text] [Related]
10. Target therapy for hepatocellular carcinoma: is sorafenib for everybody?
Daniele B; Di Maio M
J Clin Gastroenterol; 2009; 43(5):389-90. PubMed ID: 19564813
[No Abstract] [Full Text] [Related]
11. Probable interaction between warfarin and bee pollen.
Hurren KM; Lewis CL
Am J Health Syst Pharm; 2010 Dec; 67(23):2034-7. PubMed ID: 21098375
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib-induced destructive thyroiditis.
Iavarone M; Perrino M; Viganò M; Beck-Peccoz P; Fugazzola L
Thyroid; 2010 Sep; 20(9):1043-4. PubMed ID: 20825302
[No Abstract] [Full Text] [Related]
13. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Cheng AL; Kang YK; Chen Z; Tsao CJ; Qin S; Kim JS; Luo R; Feng J; Ye S; Yang TS; Xu J; Sun Y; Liang H; Liu J; Wang J; Tak WY; Pan H; Burock K; Zou J; Voliotis D; Guan Z
Lancet Oncol; 2009 Jan; 10(1):25-34. PubMed ID: 19095497
[TBL] [Abstract][Full Text] [Related]
14. Probable interaction between warfarin and marijuana smoking.
Yamreudeewong W; Wong HK; Brausch LM; Pulley KR
Ann Pharmacother; 2009 Jul; 43(7):1347-53. PubMed ID: 19531696
[TBL] [Abstract][Full Text] [Related]
15. A Drug Interaction between Crizotinib and Warfarin in Non-Small-Cell Lung Cancer: A Case Report.
Kubomura Y; Ise Y; Wako T; Katayama S; Noro R; Kubota K
J Nippon Med Sch; 2017; 84(6):291-293. PubMed ID: 29279560
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib: in hepatocellular carcinoma.
Simpson D; Keating GM
Drugs; 2008; 68(2):251-8. PubMed ID: 18197728
[TBL] [Abstract][Full Text] [Related]
17. [A Case with the Increased PT-INR after the Addition of Mirtazapine to Warfarin Therapy].
Nishimura H; Kawakami M
Seishin Shinkeigaku Zasshi; 2015; 117(10):820-5. PubMed ID: 26827407
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib, risk of bleeding and spontaneous rupture of hepatocellular carcinoma. A clinical case.
Rombolà F; Caravetta A; Mollo F; Spinoso A; Peluso L; Guarino R
Acta Medica (Hradec Kralove); 2011; 54(4):177-9. PubMed ID: 22283115
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient.
Huang WS; Yang CH
World J Gastroenterol; 2009 Sep; 15(35):4464-6. PubMed ID: 19764104
[TBL] [Abstract][Full Text] [Related]
20. A potential interaction between warfarin and atovaquone.
Hidalgo K; Lyles A; Dean SR
Ann Pharmacother; 2011 Jan; 45(1):e3. PubMed ID: 21189363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
